Double-blind parallel study of Omega-3 fatty acid supplement in patients with refractory epilepsy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14235435

Enrollment

Registered

2003-09-12

Start date

2003-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases: Epilepsy Nervous System Diseases Epilepsy

Interventions

1. Omega-3 fatty acid 2. Olive oil

Eligibility

Inclusion criteria

Inclusion criteria: Not provided at time of registration

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Seizure frequency and adverse events	—

Secondary

Measure	Time frame
1. Antiepileptic drug (AED) levels 2. Patients' global impression 3. Behaviour and mood probes 4. Hamilton Depression rating scale 5 Plasma and red blood cell (RBC) fatty acid concentrations 6. Magnetic resonance (MR) spectroscopic measurement of phosphomonoester and phosphodiester 6. Changes in total brain volume	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026